Everest Ventures

Legendsemi is a company dedicated to the development and design of high-performance analog and mixed-signal chips. It specializes in creating mid-to-high-end digital-analog hybrid products, focusing on the research and development of semiconductor solutions that primarily involve high-precision signal chains and signal chain microcontrollers or system-on-chips. Through its innovative approach, Legendsemi aims to deliver advanced technology that meets the demands of modern electronic applications.

Evrynet is a developer of an advanced financial services platform that facilitates the creation of centralized and decentralized finance (CeDeFi) applications. The company's infrastructure utilizes blockchain technology to offer fundamental financial templates, serving as a foundation for more complex financial functions and decentralized finance applications. Evrynet's platform incorporates smart contracts, allowing both individuals and enterprises to easily develop financial applications that are interoperable with various leading blockchains. This capability enables a seamless integration of diverse financial services, catering to the needs of developers and businesses in the evolving landscape of finance.

XCarnival is a crypto influencer focused on developing innovative financial services. It specializes in constructing non-standard asset leasing, pawning, and lending platforms.

7SIGNAL specializes in enterprise wireless network monitoring. Its cloud-based platform continuously assesses wireless networks, pinpointing elusive issues affecting application performance. By focusing on the 'edge' of networks where user experience is crucial, it enhances employee productivity and operational efficiency. Deployed globally across Fortune 500 companies, hospitals, and large venues.

Suzhou Ribo Life Science Co., Ltd. is a biotechnology company specializing in the development of nucleic acid drugs based on RNA interference (RNAi) technology. Established in 2007 and located in Kunshan, China, the company focuses on various aspects of RNAi, including drug discovery, siRNA design and screening, chemical modification, delivery technology, pharmacodynamics/pharmacokinetics studies, safety evaluation, and clinical trials. Suzhou Ribo Life Science develops siRNA therapeutics targeting conditions such as Hepatitis B, breast carcinoma, liver fibrosis, liver carcinoma, and HIV. The company has formed a strategic partnership with Quark Pharmaceuticals, Inc. to enhance its capabilities in the field. Through its innovative approach, Suzhou Ribo Life Science aims to provide more effective pharmaceutical solutions for healthcare providers and patients.